Stability problems see Pfizer recall pain drug Embeda acquired in King deal
Within a couple of weeks of finally acquiring King Pharmacueticals for $3.6 billion, global drugs behemoth Pfizer (NYSE: PFE) has been obliged to pull sales of the recently launched opiod painkiller Embeda (morphine sulfate and naltrexone hydrochloride).
On the official web site for Embeda, King said it has voluntarily recalled from US wholesalers and retailers all dosage forms of the drug because a pre-specified stability requirement was not met during routine testing. Available data suggest that the issue is unlikely to pose a safety risk to patients using Embeda as prescribed, and the company will continue to monitor this issue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze